Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicorette, Tylenol Ease J&J's Consumer Pain From Slow Oral Care Sales

Executive Summary

J&J’s worldwide OTC drug division sales rose 4.4% to $1bn, driven by the Tylenol and Nicorette brands, the firm reports Oct. 17. Those revenues helped offset softness in the firm’s Listerine and other oral care products due to more competition online from start-ups selling straight to consumers.

You may also be interested in...



Potential Buyers Assess Available OTC Assets From Disparate Views

As Merck KGAA and Pfizer shop their consumer health businesses, large pharmas J&J, Bayer AG and Sanofi, health and household care marketer Reckitt Benckiser and a smaller firm expanding its OTC focus, Prestige Brands, are among the firms with reasons to consider changing their own consumer health lineups.

Potential Buyers Assess Available OTC Assets From Disparate Views

As Merck KGAA and Pfizer shop their consumer health businesses, large pharmas J&J, Bayer AG and Sanofi, health and household care marketer Reckitt Benckiser and a smaller firm expanding its OTC focus, Prestige Brands, are among the firms with reasons to consider changing their own consumer health lineups.

J&J Immunology Growth Now Hinges On Stelara, Tremfya After RA Setback

The company said it will pull global regulatory filings for the interleukin-6 inhibitor sirukumab for rheumatoid arthritis after determining regulatory delays would put it too far behind the competition.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel